Cite
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
MLA
You, Benoit, et al. “Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.” Journal of Clinical Oncology, vol. 40, no. 34, Dec. 2022, pp. 3965–74. EBSCOhost, https://doi.org/10.1200/JCO.22.01207.
APA
You, B., Purdy, C., Copeland, L. J., Swisher, E. M., Bookman, M. A., Fleming, G., Coleman, R., Randall, L. M., Tewari, K. S., Monk, B. J., Mannel, R. S., Walker, J. L., Cappuccini, F., Cohn, D., Muzaffar, M., Mutch, D., Wahner-Hendrickson, A., Martin, L., Colomban, O., & Burger, R. A. (2022). Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. Journal of Clinical Oncology, 40(34), 3965–3974. https://doi.org/10.1200/JCO.22.01207
Chicago
You, Benoit, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, et al. 2022. “Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.” Journal of Clinical Oncology 40 (34): 3965–74. doi:10.1200/JCO.22.01207.